Brokerages Expect EnteroMedics Inc. (ETRM) to Post ($0.50) EPS
EnteroMedics Inc. (NASDAQ:ETRM) has been given a consensus broker rating score of 2.00 (Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation and one has given a strong buy recommendation to the company.
Brokerages have set a twelve-month consensus target price of $1.10 for the company and are forecasting that the company will post ($0.50) earnings per share for the current quarter, according to Zacks. Zacks has also assigned EnteroMedics an industry rank of 112 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research lowered EnteroMedics from a “buy” rating to a “hold” rating in a report on Wednesday, October 5th.
EnteroMedics (NASDAQ:ETRM) opened at 0.1027 on Thursday. The firm has a 50-day moving average price of $0.14 and a 200 day moving average price of $0.41. The firm’s market capitalization is $2.80 million. EnteroMedics has a one year low of $0.10 and a one year high of $4.95.
EnteroMedics (NASDAQ:ETRM) last released its earnings results on Thursday, August 4th. The medical device company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.26. EnteroMedics had a negative return on equity of 1,361.34% and a negative net margin of 4,157.93%. Analysts anticipate that EnteroMedics will post ($2.37) EPS for the current fiscal year.
EnteroMedics Inc (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for EnteroMedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EnteroMedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.